indalpine

Indalpine is a small molecule antidepressant that was one of the first selective serotonin reuptake inhibitors (SSRIs) to reach the market. It was developed in the late 1970s and introduced for medical use in France in 1983, primarily for the treatment of depression and anxiety. Indalpine acts by selectively inhibiting the reuptake of serotonin (5-hydroxytryptamine, or 5HT), thereby increasing its availability in synaptic clefts. It also exhibits antihistaminic properties. The drug was withdrawn from markets after reports of hematological toxicity, including neutropenia and agranulocytosis, as well as concerns about hepatic carcinogenicity[1][2][4][5].

Brand names

UpstèneUpstene

Other names

indalpine monohydrochlorideLipsteneIndalpino(3-indolyl-2-ethyl)piperidine4-(2-(3-indolyl)ethyl)piperidine